As previously disclosed, on October 8, 2014, Impax Laboratories (Nasdaq: IPXL) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Tower Holdings, Inc. (“Tower”), Lineage Therapeutics Inc. (“Lineage”), …
Though recent challenges with its manufacturing facility in Hayward, CA involving an FDA Warning Letter & multiple …
Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Compass Diversified Holdings (CODI): Free Stock Analysis Report Impax Laboratories, Inc. (IPXL): Free Stock Analysis Report
The Wall Street Journal reported Thursday afternoon that Impax Laboratories Inc. (IPXL) is in merger talks with privately ... of 2.25 at $23.80 with volume at nearly a 6-month high. The stock surged to an 11-month high.
Impax Laboratories Inc. (NASDAQ: IPXL) dropped about 28% on Tuesday to post a new 52-week low of $22.08 after closing at $30.59 on Monday. The stock’s 52-week high is $47.48. Volume reached nearly 10 times the daily average of …
UBS downgraded Impax Laboratories Inc (NASDAQ: IPXL) Thursday from Neutral to Sell and maintained a $36 price target. Analyst Marc Goodman noted that the stock had run up on expectations that the company may get acquired or do …
Impax Laboratories Inc. IPXL reported third-quarter 2017 adjusted earnings of ... Amneal Pharmaceuticals entered into an all-stock deal to merge and form a new publicly traded company, Amneal Pharmaceuticals Inc. The combined company …